Hyperkalemia Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 16.79 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hyperkalemia Treatment Market Analysis
The hyperkalemia treatment market is poised to register a CAGR of 16.79% over the forecast period.
The COVID-19 pandemic impacted the market significantly during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of COVID-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and COVID-19. For instance, according to an article published by PubMed in August 2021, there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. and concluded that there is a correlation between COVID-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the increasing prevalence of hyperkalemia, the rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market's growth. For instance, the article published by Healthline in March 2022 stated that high potassium levels, or hyperkalemia (HK), affect 40% to 50% of people with chronic kidney disease (CKD) globally, and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.
In addition, another article published by PubMed Central in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such disease prevalence is expected to necessitate the availability of drugs and diagnostics to the target population, contributing to the market's growth.
Therefore, owing to the above-mentioned factors, such as the increasing prevalence of hyperkalemia and the rising focus on research and development, the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder market growth over the forecast period.
Hyperkalemia Treatment Market Trends
This section covers the major market trends shaping the Hyperkalemia Treatment Market according to our research experts:
Chronic Hyperkalemia Segment is Anticipated to Witness Significant Growth Over the Forecast Period
Heart failure (HF) and chronic kidney disease (CKD) patients frequently have chronic hyperkalemia (cHK), a significant medical condition that can have detrimental effects and call for cautious management by cardiologists or nephrologists. Therefore, owing to the severity of the disease, the cHK segment is anticipated to witness growth over the forecast period.
According to the data updated by the National Kidney Foundation in 2022, it was shown that when HK develops abruptly and potassium levels become extremely high, patients can experience chest pain, nausea, vomiting, shortness of breath, and heart palpitations. Also, severe or chronic hyperkalemia can be a life-threatening condition that necessitates urgent medical attention for the patient's survival. Thus, the seriousness of the disease among the target population is expected to fuel the demand for drugs available for treatment, which is anticipated to drive market growth.
Furthermore, the research article published by PubMed in June 2021 mentioned that when a cohort study of 1,499 patients with cHK and CKD, heart failure, or diabetes mellitus was conducted with a 36-month follow-up,, the annual healthcare cost per patient with cHK was calculated to be double that of mild hyperkalemia. Hence, the burden of the condition requires more targeted drugs or therapies for treatment, which is further expected to drive segment growth.
As a result of factors such as the high prevalence of hyperkalemia, the segment is expected to grow during the analysis period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is anticipated to witness growth over the forecast period and have a significant market share. Among other countries in the region, the United States is leading the market due to factors such as an increase in healthcare expenditure, increasing research and developments, and the rising prevalence of hyperkalemia.
As per the article published by PubMed in October 2021, HK contributes to nearly 800,000 emergency department visits annually in the United States, and the prevalence of the disease is growing owing to the aging population and the growth in associated comorbidities. Such a high burden of disease in the country is anticipated to demand the availability and development of advanced and effective drugs in the country. thereby driving the overall market growth in the region.
Furthermore, according to an article published by the Canadian Medical Association Journal in December 2021, in Canada, emergency department use is high among patients with CKD. Observational studies have associated hyperkalemia with increased hospital and intensive care unit admissions in Canada, and it was found that hyperkalemia accounts for 48% of all ambulatory care-sensitive conditions among patients on dialysis. Hence, the high burden of hyperkalemia in Canada is also expected to drive market growth.
In addition, the data updated by the CDC in February 2022 shows that in the United States, nearly 37 million adults are estimated to have CKD, and 40% of people who live with severely reduced kidney function are not aware of having CKD. Additionally, as per the source mentioned above, approximately 360 people begin dialysis treatment for kidney failure every 24 hours in the country. Thus, the burden of CKD is anticipated to increase the risk of hyperkalemia among the target population. This is expected to create urgent treatment options for the condition. which is further predicted to drive the market's growth over the analysis period.
Therefore, owing to the factors mentioned above, such as the increasing prevalence of hyperkalemia and chronic kidney disease, the market studied is anticipated to witness growth in the region.
Hyperkalemia Treatment Industry Overview
The hyperkalemia treatment market is consolidated globally and regionally and is dominated by a few players. A few key players in the market are AstraZeneca, Ardelyx, CSL Limited (Vifor Pharma Management Ltd.), Sanofi SA, and Perrigo Company PLC, among others.
Hyperkalemia Treatment Market Leaders
-
Sanofi S.A.
-
Perrigo Company plc
-
CSL Limited (Vifor Pharma Management Ltd.)
-
AstraZeneca
-
Ardelyx
*Disclaimer: Major Players sorted in no particular order
Hyperkalemia Treatment Market News
- January 2022: The National Institute of Health and Care Excellence (NICE) updated its guideline for AstraZeneca's Lokelma (sodium zirconium cyclosilicate) in chronic kidney disease (CKD)-related hyperkalemia (HK). In the United Kingdom, this updated recommendation will make it easier for patients to obtain the medication outside of hospitals.
- December 2021: Vifor Pharma declared positive findings in the completed phase IIIb DIAMOND trial of Veltassa in heart failure patients with either manifest hyperkalemia or a history of hyperkalemia while treated with renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
Hyperkalemia Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hyperkalemia
4.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances
4.3 Market Restraints
4.3.1 High Cost of Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug
5.1.1 Sodium Zirconium Cyclosilicate
5.1.2 Beta2 Agonist
5.1.3 Sodium Polystyrene Sulfonate
5.1.4 Other Drugs
5.2 By Type of Disease
5.2.1 Acute Hyperkalemia
5.2.2 Chronic Hyperkalemia
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Ardelyx
6.1.3 Perrigo Company PLC
6.1.4 Sanofi SA
6.1.5 Odan Laboratories Ltd
6.1.6 AdvaCare International
6.1.7 Steadfast MediShield Pvt. Ltd.
6.1.8 CSL Limited (Vifor Pharma Management Ltd.)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hyperkalemia Treatment Industry Segmentation
According to the scope of this report, hyperkalemia (HK), a condition characterized by elevated serum potassium, is caused by disturbances in potassium homeostasis within the body. The hyperkalemia treatment market is segmented by drug (Sodium Zirconium Cyclosilicate, Beta2-Agonist, Sodium Polystyrene Sulfonate, and Other Drugs), type of disease (Acute Hyperkalemia and Chronic Hyperkalemia), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug | |
| Sodium Zirconium Cyclosilicate | |
| Beta2 Agonist | |
| Sodium Polystyrene Sulfonate | |
| Other Drugs |
| By Type of Disease | |
| Acute Hyperkalemia | |
| Chronic Hyperkalemia |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hyperkalemia Treatment Market Research FAQs
What is the current Hyperkalemia Treatment Market size?
The Hyperkalemia Treatment Market is projected to register a CAGR of 16.79% during the forecast period (2024-2029)
Who are the key players in Hyperkalemia Treatment Market?
Sanofi S.A., Perrigo Company plc, CSL Limited (Vifor Pharma Management Ltd.), AstraZeneca and Ardelyx are the major companies operating in the Hyperkalemia Treatment Market.
Which is the fastest growing region in Hyperkalemia Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Hyperkalemia Treatment Market?
In 2024, the North America accounts for the largest market share in Hyperkalemia Treatment Market.
What years does this Hyperkalemia Treatment Market cover?
The report covers the Hyperkalemia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hyperkalemia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hyperkalemia Treatment Industry Report
Statistics for the 2023 Hyperkalemia Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hyperkalemia Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
